Gene Therapy Clinical Trials
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: high dose chemotherapy then autologous hematopoietic cell transplant
Eligibility
Inclusion Criteria:- must be in remission
- adequate organ function Exclusion Criteria:- prior MDS
- active infection
- liver disease
Ages Eligible for Study
16 Years - 69 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting